Efficacy of niosomal formulation of diallyl sulfide against experimental candidiasis in Swiss albino mice

Nanomedicine

Volumn 4, Issue 7, 2009, Pages 713-724

  Alam, Maroof ^a   Dwivedi, Varun ^b   Khan, Aijaz Ahmed ^c   Mohammad, Owais ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

^b OHIO STATE UNIVERSITY   (United States)

^c ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Antifungal efficacy; Candidiasis; Diallyl sulfide; Drug delivery; Garlic; Intracellular pathogen; Niosomes; Sorbitan monooleate

Indexed keywords

ALANINE AMINOTRANSFERASE; ALLYL SULFIDE; AMPHOTERICIN B; BILIRUBIN; CREATININE; FLUCONAZOLE; GARLIC OIL; LIPOSOME; SORBITAN OLEATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG PURITY; DRUG RELEASE; DRUG STRUCTURE; FEMALE; FUNGAL STRAIN; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; TOXICITY TESTING; ZETA POTENTIAL;

ALLYL COMPOUNDS; ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; FEMALE; MICE; NANOTECHNOLOGY; SULFIDES; UNILAMELLAR LIPOSOMES;

EID: 73549101707     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.09.60     Document Type: Article

References (39)

1. Anaissie EJ: Opportunistic mycoses in the immunocompromised host: experience at cancer center and review. Clin. Infect. Dis. 14, 43-53 (1992).
2. Pfaller MA, Webzel R: The impact of changing epidemiology of fungal infections in the 1990s. Eur. J. Clin. Microbiol. Infect. Dis. 11, 287-291 (1992).
3. Richardson MD: Opportunistic and pathogenic fungi. J. Antimicrob. Chemother. 28, 1-11 (1991).
4. Walsh TJ: Invasive fungal infections: problems and challenges in developing new antifungal compound. In: Emerging Targets in Antibacterial and Antifungal. Sutcliffe J, Georgopapadakou NH (Eds). Chapman & Hall, NY, USA, 249-373 (1992). • Highlights the problems increasingly encountered when treating intracellular fungal infections.
5. Rex JH, Chester R, Cooper JR, Merz WG, Galgiani JN, Anaissie EJ: Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob. Agents Chemother. 39, 906-909 (1995).
6. Pai ST, Platt MW: Antifungal effects of Allium sativum (garlic) extracts against the Aspergillus species involved in otomycosis. Lett. Appl. Microbiol. 20, 14-18 (1995).
7. Lawson LD: Garlic: a review of its medicinal effects and indicated active compounds. In: Phytomedicines of Europe: Their Chemistry and Biological Activity. Lawson LD, Bauer R (Eds). American Chemical Society, Washington, DC, USA, 176-209 (1998). •• One of the most comprehensive commentaries on the antimicrobial properties of garlic and garlic-derived compounds.
8. Yoshida S, Katsuzaki H, Ohta R: An organosulphur compound isolated from oil-macerated garlic extract, and its antimicrobial effect. Biosci. Biotechnol. Biochem. 63, 588-590 (1999).
9. Agarwal KC: Therapeutic actions of garlic constituents. Med. Res. Rev. 16, 111-124 (1996). • Discusses the various medicinal uses of garlic compounds and the basis of their respective medicinal properties.
10. Lawson LD, Wang ZJ, Hughes BG: Identification and HPLC quantification of the sulphides and dialk(en)yl thiosulphinates in commercial garlic products. Planta Med. 57, 363-370 (1991). • Involves identification of the allyl sulphide constituents of garlic and garlic oil.
11. Tsao SM, Yin MC: In vitro antimicrobial activity of four diallyl sulphides occurring naturally in garlic and Chinese leek oils. J. Med. Microbiol. 50, 646-649 (2001). •• Determines the antimicrobial activity of allyl sulfides of garlic oil.
12. Khan MA, Nasti TH, Saima K: Co-administration of immunomodulator tuftsin and liposomised nystatin can combat less susceptible Candida albicans infection in temporarily neutropenic mice. FEMS Immunol. Med. Microbiol. 41, 249-258 (2004).
13. Baillie AJ, Coombs GH, Dolan TF: Non-ionic surfactant vesicles, niosomes, as delivery system for the anti-leishmanial drug, sodium stribogluconate. J. Pharm. Pharmacol. 38, 502-505 (1986). •• Pioneering research article on the usability of niosomal vesicles as drug delivery carriers.
14. Kotler-Brajtburg J, Medoff G, Kobayashi GS: Classification of polyene antibiotics according to chemical structure and biological effects. Antimicrob. Agents Chemother. 15, 716-722 (1979).
15. Nounou MM, El-Khordagui LK, Khalafalla NA: In vitro release of hydrophilic and hydrophobic drugs from liposomal dispersions and gels. Acta Pharm. 56, 311-324 (2006).
16. Khan MA, Syed FM, Nasti HT: Use of tuftsin bearing nystatin liposomes against an isolate of Candida albicans showing less in vivo susceptibility to amphotericin B. J. Drug Target. 11, 93-99 (2002).
17. Khan AA: Wallerian degeneration in the optic nerve of rabbit. Cells Tissue Organs 177, 104-109 (2004).
18. National Committee for Clinical Laboratory Standards (NCCLS): Reference method for broth dilution antifungal susceptibility testing for yeasts. Approved standard M 27-A. NCCLS, Villanova, PA, USA (1995).
19. Hurtrel B, Lagrange PH, Michel JC: Systemic candidiasis in mice. II. Main role of polymorphonuclear leukocytes in resistance to infection. Ann. Immunol. 131, 105-109 (1980).
20. Baccarini M, Bistoni F, Pucceti P: Natural cell-mediated cytotoxicity against Candida albicans induced by cyclophosphamide: nature of the in vitro cytotoxicity effector. Infect. Immun. 42, 1-7 (1983).
21. Nguyen MH, Peacock JE, Morris AJ: The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am. J. Med. 100, 617-623 (1996).
22. Banerjee SN, Emori TG, Culver DH: Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. Am. J. Med. 91(3B) 86S-89S (1991).
23. Goff DA, Koletar SL, Buesching WJ: Isolation of fluconazole resistant Candida albicans from human immunodeficiency virus-negative patients never treated with azoles. Clin. Infect. Dis. 20, 77-83 (1995).
24. Shah PM: The need for new therapeutic agents: what is in the pipeline? Clin. Microbiol. Infect. 11, 36-42 (2005).
25. Yin MC, Tsao SM: Inhibitory effect of seven Allium plants upon three Aspergillus species. Int. J. Food Microbiol. 49, 49-56 (1999).
26. Reuter HD, Koch HP, Lawson LD: Therapeutic effects and applications of garlic and its preparations. In: Garlic. The science and therapeutic application of Allium sativum L. and related species. Koch HP, Lawson LD (Eds). Williams & Wilkins, Baltimore, MD, USA, 135-212 (1996).
27. Cavallito CJ, Bailey JH: Allicin, the antibacterial principle of Allium sativum. I. Isolation, physical properties, and antibacterial action. J. Am. Chem. Soc. 66, 1950 (1944).
28. Cavallito CJ, Buck JS, Suter CM: Allicin, the antibacterial principle of Allium sativum. II. Determination of the chemical structure. J. Am. Chem. Soc. 66, 1952-1954 (1944).
29. Cavallito CJ, Bailey JH, Buck J: Allicin, the antibacterial principle of Allium sativum. III. Its precursor and "essential oil" of garlic. J. Am. Chem. Soc. 67, 1032 (1945).
30. Lemar KM, Passa O, Aon MA et al.: Allyl alcohol and garlic (Allium sativum) extract produce oxidative stress in Candida albicans. Microbiology 151, 3257-3265 (2005). •• Studies the anti-Candida mechanism of garlic extracts.
31. Lemar KM, Muller CT, Plummer S, Lloyd D: Cell death mechanisms in the human opportunistic pathogen Candida albicans. J. Eukaryot. Microbiol. 50(Suppl.), 685-686 (2003).
32. Lemar KM, Aon MA, Cortassa S, O'Rourke B, Muller CT, Lloyd D: Diallyl disulphide depletes glutathione in Candida albicans: oxidative stress-mediated cell death studied by two-photon microscopy. Yeast 24(8), 695-706 (2007).
33. Lemar KM, Turner MP, Lloyd D: Garlic (Allium sativum) as an anti-Candida agent: a comparison of the efficacy of fresh garlic and freeze-dried extracts. J. Appl. Microbiol. 93(3), 398-405 (2002).
34. Khan A, Shukla Y, Kalra N et al.: Potential of diallyl sulfide bearing pH-sensitive liposomes in chemoprevention against DMBA-induced skin papilloma. Mol. Med. 13(7-8), 443-451 (2007).
35. Sun XH, Guo T, He J, Zhao MH, Nie SF: Tissue distribution of solid lipid nanoparticles loaded garlic oil in rats. Zhongguo Zhong Yao Za Zhi 33(23), 2772-2775 (2008).
36. Luo DQ, Guo JH, Wang FJ et al.: Antifungal efficacy of polybutylcyanoacrylate nanoparticles of allicin and comparison with pure allicin. J. Biomater. Sci. Polym. Ed. 20(1), 21-31 (2009).
37. Zhang ZM, Yang XY, Deng SH, Xu W, Gao HQ: Anti-tumor effects of polybutylcyanoacrylate nanoparticles of diallyl trisulfide on orthotopic transplantation tumor model of hepatocellular carcinoma in BALB/c nude mice. Chin. Med. J. 120(15), 1336-1342 (2007).
38. Florence AT: New drug delivery systems. Chem. Ind. 20, 1000-1004 (1993). •• Discusses the recent trends in delivery systems being increasingly used in modern medicine.
39. Sihorkar V, Vyas SP: Polysaccharide coated niosome for oral drug delivery formulation and in vitro stability studies. Pharmazie 55(2), 107-113 (2000).